Clinical trials: Semaglutide
Non-alcoholic Steatohepatitis
A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
Novo Nordisk is developing a combination of 2 medicines (NNC0194-0499 and semaglutide) for the treatment of nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT05766709
- Testing
- NNC0194-0499, Semaglutide, NNC0194-0499/Semaglutide A (40/3.20 mg/mL)
- Where
- Canada
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Caloric Restriction, Body Composition
Long-Term Effects of Semaglutide on Body Composition and Performance in Running
Semaglutide, a GLP-1 receptor agonist, has demonstrated significant weight-loss effects in people with obesity and/or type 2 diabetes, but its impact on exercise performance among lean, fit athletes remains unknown.
- Conditions
- Caloric Restriction, Body Composition, Performance
- Trial name
- NCT07874932
- Testing
- Semaglutide (SEMA)
- Where
- Denmark
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Morten Hostrup, PhD
Healthy Volunteers, Type 2 Diabetes
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets
In this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested.
- Trial name
- NCT04109508
- Testing
- Oral semaglutide
- Where
- Germany
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers (Diabetes Mellitus, Type 2)
A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide
In this trial, two approved solutions of the medicine semaglutide will be compared in healthy volunteers. The purpose of this trial is to see if semaglutide B and semaglutide D solutions are comparable with regards to moving…
- Trial name
- NCT05232708
- Testing
- Semaglutide B, 1.34 mg/mL, Semaglutide D, 1.0 mg/mL
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects
This trial is conducted in Europe. The aim of the trial is to investigate the absorption, metabolism and excretion after a single subcutaneous dose of [3H]-semaglutide in healthy male subjects.
- Trial name
- NCT02060266
- Testing
- semaglutide
- Where
- Netherlands
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Normal Weight, Overweight and Obesity
Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design.
- Conditions
- Normal Weight, Overweight and Obesity, Insulin Sensitivity, Insulin Resistance
- Trial name
- NCT06487832
- Testing
- Subcutaneous GLP1-RA
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Class I/II Obesity
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
The goal of this clinical trial is to learn about the nature of brain abnormalities associated with excess body fat in healthy adults aged 35-55.
- Trial name
- THRIVE (NCT07592546)
- Testing
- semaglutide
- Where
- Canada
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Alain Dagher
Healthy Participants
A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants
In this study, a known investigational medicine called 'semaglutide' will be tested in 2 different tablet versions. In addition to semaglutide, the tablet versions contain different helping agents in different amounts.
- Trial name
- NCT05784402
- Testing
- Semaglutide J, Semaglutide C
- Where
- 3 sites in United States, Canada
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight, Cardiometabolic Health Indicators
Tirzepatide Impact Assessment Study
This study examines how two different weight-loss strategies affect heart and metabolic health, as well as changes at the molecular level in the body.
- Conditions
- Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders
- Trial name
- TIA (NCT07740291)
- Testing
- GLP-1 Receptor Agonist Therapy, Structured Lifestyle Intervention
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Texas Tech University
Schizophrenia Disorder, Metabolic Syndrome
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Patients with schizophrenia on second-generation antipsychotics have a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options.
- Conditions
- Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk
- Trial name
- NCT07770282
- Testing
- Semaglutide + TAU
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Diabetes Mellitus, Type 2
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men
This study looks at how the new medicine called NNC0480-0389 works in the body of Chinese men when it is given at different doses together with a fixed dose of semaglutide.
- Trial name
- NCT05498610
- Testing
- NNC0480 0389, Semaglutide
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects
This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability and pharmacokinetics (the effect of the investigated drug on the body) of single and multiple doses of a long-acting GLP-1…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01866748
- Testing
- semaglutide
- Where
- Germany
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects
This trial is conducted in Europe and Asia. The aim of the trial is to investigate the influence of semaglutide on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02022254
- Testing
- semaglutide, metformin, warfarin
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy
A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
The goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate and semaglutide alone or at the same time.
- Trial name
- NCT06699329
- Testing
- Enlicitide Decanoate, Semaglutide
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), and the safety and…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02146079
- Testing
- semaglutide
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Participants
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III
In this study, a known medicine called 'semaglutide' will be tested in two different tablet versions. The two tablets differ in the way these have been manufactured.
- Trial name
- NCT06097390
- Testing
- Semaglutide
- Where
- Canada
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools
This study will compare four different semaglutide versions and different injection tools. The study aims to show similar levels of semaglutide in the blood using different versions of semaglutide.
- Trial name
- NCT03598621
- Testing
- Semaglutide, 0.5 mg/mL, Semaglutide, 1.0 mg/mL, Semaglutide, 1.34 mg/mL
- Where
- 2 sites in Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
PreDiabetes, Prediabetic State
Genetics of the Acute Response to Oral Semaglutide
The study aims to investigate the genetic basis of the response to short-term (3 months) orally administered semaglutide treatment, in terms of improving metabolic parameters, including the hormonal response to a standardized…
- Conditions
- PreDiabetes, Prediabetic State, Obesity
- Trial name
- GAROS (NCT05340868)
- Testing
- Semaglutide Pill
- Where
- Poland
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Medical University of Bialystok
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects
This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), safety and…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02161588
- Testing
- semaglutide
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide.
- Trial name
- NCT05671653
- Testing
- PF-07081532, Semaglutide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer